Home

2025 Year in Review

A Message from the SITC President

For more than four decades, the Society for Immunotherapy of Cancer (SITC) has been guided by a singular mission: to improve outcomes for patients by advancing the science, development, and application of cancer immunotherapy. In a year marked by both complexity and innovation, the SITC family rose to the moment, advancing our strategic priorities with focus, resilience and purpose.

Building on the momentum of our strategic vision and the #SITCQuestfor100 initiative — our bold commitment to achieving 100 novel immuno-oncology agents approved by 2034 — SITC embraced new opportunities and elevated critical conversations across the field. Even amid a challenging external landscape, our leadership remained forward-looking and action-oriented.

Read full letter >

#SITCQuestfor100

With six transformative, innovative, and diverse strategic goals, SITC set a vision for 100 novel immuno-oncology agents approved by 2034. Join our quest to develop a diverse portfolio of agents, expand into earlier lines of therapy, explore AI solutions, and broaden our community tent.

Learn More

Numbers at a Glance

Total Members: 4235
  • 1,252 Student Members
  • 1,025 International Members

Total unique Volunteers: 868
  • 549 Committee members
  • 27 Committees

Learn More

Strategic Goals

Education and Scientific Exchange

Serve as the leading resource for information and education on cancer immunotherapy.

Add link to resource here

Professional Standards

Set industry standards for the field of cancer immunotherapy.

Add link to resource here

Global Access and Impact

Advance the science and application of, and equitable access to, cancer immunotherapy worldwide to eliminate disparities and improve outcomes.

Add link to resource here

Policy and Advocacy

Inform and influence the research, regulation, quality of patient care and equity of patient access impacted by public policy.

Add link to resource here

Science and Research

Challenge the thinking, seek and advance the best research to improve outcomes and develop tumor immunology and cancer immunotherapy.

Add link to resource here

Leadership Development

Cultivate the next generation of diverse leaders and innovators in tumor immunology and cancer immunotherapy.

Add link to resource here

Forward Fund

The SITC Forward Fund enables SITC to further the society’s mission and expand the knowledge of and interest in cancer immunotherapy. With the investment from the Forward Fund, SITC has awarded more than $6 million in research funding to early career investigators in the last decade. In 2025, SITC supported nearly 80 awards for early career scientists.

Image card link goes here*

Honors and Recognition

Each year, SITC celebrates legends in the field who have contributed immeasurably to advancing the science and application of immunotherapy. These individuals serve as a source of inspiration to the next generation and a represent decades of progress for cancer patients everywhere.


Image card link goes here*